RINVOQ is now approved as the first and only oral JAK inhibitor for adults with active non-radiographic axial spondyloarthritis (nr-axSpA) RINVOQ is the first and only JAK inhibitor approved for both active ankylosing spondylitis (AS) and nr-axSpA1-3 In a clinical study, RINVOQ delivered…
Related Posts
LATIN AMERICA’S 50 BEST RESTAURANTS REVEALS THE INAUGURAL LIST OF RESTAURANTS RANKED BETWEEN 51ST AND 100TH FOR 2022
The 51-100 list, presented in association with American Express, is revealed ahead of the annual awards ceremony for Latin America’s 50 Best Restaurants LONDON, Nov. 3, 2022 /PRNewswire/ — Latin America’s 50 Best Restaurants is celebrating a greater number of hospitality establishments…
Sabre Elects Rachel Gonzalez to its Board of Directors
Former Sabre executive brings significant business, governance and legal acumen to the board SOUTHLAKE, Texas, Oct. 20, 2022 /PRNewswire/ — Sabre Corporation (NASDAQ: SABR), a leading software and technology provider that powers the global travel industry, today announced that the…
Major eBetting Companies Working Hard to Simplify Operations for a More Pleasurable Experience
FinancialNewsMedia.com News Commentary PALM BEACH, Fla., June 17, 2022 /PRNewswire/ — The global sports betting markets, unlike most, grew during the pandemic and are projected to continue to grow for years to come. The demand for sports betting is driven by factors like the shifting…